Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells
暂无分享,去创建一个
Satohiro Masuda | Tomoko Sato | S. Masuda | K. Inui | T. Terada | Ken-ichi Inui | T. Katsura | Toshiya Katsura | Masahiro Tsuda | Tomoko Sato | M. Tsuda | Tomohiro Terada | Miki Ueba | Miki Ueba
[1] B. Feng,et al. Effect of Human Renal Cationic Transporter Inhibition on the Pharmacokinetics of Varenicline, a New Therapy for Smoking Cessation: An In Vitro–In Vivo Study , 2008, Clinical pharmacology and therapeutics.
[2] Tomoko Sato,et al. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. , 2008, Biochemical pharmacology.
[3] Hiroshi Omote,et al. A human transporter protein that mediates the final excretion step for toxic organic cations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[4] J. Shin,et al. Genetic Variants of the Organic Cation Transporter 2 Influence the Disposition of Metformin , 2008, Clinical pharmacology and therapeutics.
[5] K. Inui,et al. Oppositely directed H+ gradient functions as a driving force of rat H+/organic cation antiporter MATE1. , 2007, American journal of physiology. Renal physiology.
[6] A. Somogyi,et al. Reduction of metformin renal tubular secretion by cimetidine in man. , 1987, British journal of clinical pharmacology.
[7] H. Kasanuki,et al. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans , 2000, Clinical pharmacology and therapeutics.
[8] S. Masuda,et al. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. , 2007, Biochemical pharmacology.
[9] H. Takane,et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin , 2006, Journal of Human Genetics.
[10] H. Saito,et al. Mechanisms of gentamicin transport in kidney epithelial cell line (LLC-PK1). , 1986, The Journal of pharmacology and experimental therapeutics.
[11] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[12] Brian Tomlinson,et al. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine , 2008, Pharmacogenetics and genomics.
[13] S. Masuda,et al. Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family) , 2006, Journal of Pharmacology and Experimental Therapeutics.
[14] A. Somogyi,et al. Cimetidine-procainamide pharmacokinetic interaction in man: Evidence of competition for tubular secretion of basic drugs , 2004, European Journal of Clinical Pharmacology.
[15] Meng Li,et al. Drugdrug interactions involving membrane transporters in the human kidney , 2006, Expert opinion on drug metabolism & toxicology.
[16] K. Speeg,et al. Cimetidine inhibits renal procainamide clearance , 1984, Clinical pharmacology and therapeutics.
[17] A. Somogyi,et al. Effect of cimetidine on renal and hepatic drug elimination: Studies with triamterene , 1986, Clinical pharmacology and therapeutics.
[18] S. Masuda,et al. Distinct Characteristics of Organic Cation Transporters, OCT1 and OCT2, in the Basolateral Membrane of Renal Tubules , 2001, Pharmaceutical Research.
[19] S. Higuchi,et al. Polymorphism in human organic cation transporters and metformin action. , 2008, Pharmacogenomics.
[20] Osamu Ogawa,et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. , 2007, Biochemical pharmacology.
[21] Yuichi Sugiyama,et al. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.
[22] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[23] R. Maynard,et al. The Pharmacological Basis of Therapeutics. 9th ed , 1997 .
[24] M. Okuda,et al. Creatinine Transport by Basolateral Organic Cation Transporter hOCT2 in the Human Kidney , 2004, Pharmaceutical Research.
[25] H. Koepsell,et al. Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.
[26] O. Ogawa,et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.
[27] I. Tamai,et al. TRANSPORT OF THE DOPAMINE D2 AGONIST PRAMIPEXOLE BY RAT ORGANIC CATION TRANSPORTERS OCT1 AND OCT2 IN KIDNEY , 2005, Drug Metabolism and Disposition.
[28] K. Inui,et al. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). , 2008, Biochemical pharmacology.
[29] K. Giacomini,et al. Mechanisms of interactions between organic anions and the organic cation transporter in renal brush border membrane vesicles. , 1990, Biochemical pharmacology.
[30] A. Somogyi,et al. Selectivity of the cimetidine-induced alterations in the renal handling of organic substrates in humans. Studies with anionic, cationic and zwitterionic drugs. , 1986, The Journal of pharmacology and experimental therapeutics.
[31] Christopher J Endres,et al. The role of transporters in drug interactions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.